Teva Pharmaceutical Industries Limited

Ben Z Weiner

David Ladkani

Haim Yellin

David Avnir

Jacob Herzig

Mordecai Popovtzer

Zeev Mazor

Abraham Antebi

Shmuel Edelstein

Stephan Cherkez

John A Kanis

Benjamin Shalita

A method and composition for an improved treatment of human renal osteodystrophy, comprising the administration of 6-40 mcg/d (micrograms per day) of 24,25(OH).sub.2 D.sub.3 in combination with amounts of 1-alpha(OH)D.sub. 3 or 1,25(OH).sub.2 D.sub.3 or DHT.sub.2, which will maintain in the serum of patients the calcium concentration at 10-11 mg/dl (milligrams per deciliter) and the phosphate concentration at 5.5-6.0 mg/dl (milligrams per deciliter) and the numerical multiplication product of calcium x phosphate not more than 60-65.

Combination of cholecalciferol derivatives for the treatment of renal

Novel esters of the general formula ##STR1## in which ##STR2## is the acyl residue of a non-steroidal anti-inflammatory compound containing a carboxylic acid function. The novel esters are prepared by reacting an acide R--COOH when R is as above, with 1-haloethyl ethyl carbonate. There are also provided pharmaceutical compositions containing any of the said novel esters.

Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory

4(5)-Hydroxymethyl-5(4)-methylimidazole (MHI) is prepared by a process comprising the steps of:

Preparation of 4(5)-hydroxymethyl-5(4)-methylimidazole

1'-Ethoxycarbonyloxyethyl ester of di-n-propylacetic acid, also known as valproic acid. The novel compound is prepared by reacting valproic acid with 1-haloethyl ethyl carbonate. There are also provided pharmaceutical compositions for oral administration containing the said ester.

1'-ethoxycarbonyloxyethyl ester of valproic acid, its preparation and

Growing community of inventors

Jerusalem, Israel

Ben Z Weiner